Zydus Cadila, one of the two largest manufacturers of key Covid drug hydroxychloroquine (HCQ), has ramped up its production by nearly 10X to 30 metric tonnes (15 crore tablets of 200mg) per month in view of the huge spike in demand expected due to rising cases of Covid-19. The company with over Rs 13,000-crore revenue is helping the government to build a stockpile of 10 crore dosages of the drug.He added that there are enough stocks in the country and, if need be, it can be scaled up to even 25 crore tablets. Significantly, the Ahmedabad-based company’s accelerated research for a vaccine on Covid-19 has entered the animal-testing stage. If the results are successful, the company is hopeful of its launch by January next year.They will be supplying the drug to ICMR (Indian Council of Medical Research) at a price even lower than the government-regulated price  at a little over Rs 3 per tablet.” ICMR recently advised the use of HCQ for prevention among high-risk categories  healthcare workers and relatives of confirmed patients. The government partially eased the export ban on the drug, reportedly after a US demand, which also reflected in Cadila Healthcare’s stock hitting the upper circuit and closing nearly 14% higher at Rs 313 on the BSE.Going forward, the company does not expect any production constraints on finished formulation as it also manufactures key intermediates as well as the raw materials for the drug.